Quazepam

Summary

Quazepam (CHEMBL1200472) is an approved small molecule (ATC N05CD10); indicated across 1 condition including insomnia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CD10
• Indications: 1 condition
• Chemistry: 386.8 Da · C17H11ClF4N2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200472
Name	Quazepam
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	4999
ATC	N05CD10
Molecular formula	C17H11ClF4N2S
Molecular weight	386.8
InChIKey	IKMPWMZBZSAONZ-UHFFFAOYSA-N

SMILES: C1C(=S)N(C2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F)CC(F)(F)F

IUPAC name: 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione

Also known as: Doral, NSC-309702, Quazepam, Quazepam civ, SCH 16134, SCH-16134, QUAZEPAM

Patent coverage: 2,109 distinct patent families (8,422 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,394 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
insomnia	4	MONDO:0013600	EFO:0004698

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).